Pangea Laboratory Partners with Unilabs for Cancer Assay in Europe
Pangea Laboratory Collaborates with Unilabs for Diagnostic Innovation
Pangea Laboratory has announced an exciting partnership with Unilabs, a prominent provider of clinical laboratory testing and diagnostic imaging across Europe. Together, they are introducing the Bladder CARE™ Assay, which will soon be available in Switzerland. This collaboration not only aims to enhance access to cutting-edge diagnostics but also indicates a significant push towards innovative cancer detection methodologies across the continent.
Transforming Cancer Diagnostics for Patients
With this partnership, the Bladder CARE™ Assay will be included in insurance coverage, making it more accessible for patients who may need this critical test. The strategic agreement is designed to efficiently streamline the way cancer diagnostics are conducted, ultimately benefiting patients by providing quicker and more reliable testing options throughout Europe.
Understanding the Bladder CARE™ Assay
The Bladder CARE™ Assay has received the coveted Breakthrough Device Designation from health authorities due to its remarkable capabilities. This innovative test utilizes DNA methylation biomarkers obtained from urine samples to accurately detect bladder cancer and upper tract urothelial carcinoma (UTUC). Its non-invasive nature allows patients to collect samples conveniently from home, reducing the typical stress associated with cancer diagnostic procedures.
Exceptional Sensitivity and Specificity
What sets the Bladder CARE™ Assay apart is its impressive performance metrics. With sensitivity, specificity, and negative predictive value exceeding 93% for both bladder cancer and UTUC, this assay provides quantifiable and actionable results. Such high accuracy positions it as a leading option within the market for cancer diagnostics.
Expert Opinions on the Partnership
Patrick Bornand, the Head of Pathology, Genetics & Oncology at Unilabs Switzerland, expressed enthusiasm about this collaboration, stating the partnership underscores a mutual commitment to pioneering innovations in diagnostics. According to Bornand, the introduction of the Bladder CARE™ Assay reinforces Unilabs' dedication to empowering early detection and enhancing overall patient care.
Pangea Laboratory's Vision for Non-Invasive Healthcare
Dr. Yap Ching Chew, COO of Pangea Laboratory, also shared insights into the company's philosophies. He articulated the healthcare discipline's shift towards non-invasive solutions that minimize the patient burden while still delivering highly precise diagnostic results. Dr. Chew emphasized how the shared vision between Pangea and Unilabs represents a commitment to setting new standards in cancer diagnostics.
About Pangea Laboratory
Founded in 2014, Pangea Laboratory has rapidly established itself as a leader in the diagnostics industry. The company is both CLIA-certified and accredited by the College of American Pathologists. Pangea Laboratory is dedicated to simplifying the diagnostic process for critical health conditions, ensuring that patients receive timely and accurate results.
The Role of Unilabs in European Healthcare
Unilabs is a well-respected European provider of clinical laboratory testing and medical diagnostic imaging services. With over 109 laboratories and 44 imaging units spread across 12 countries, Unilabs conducts upwards of 106 million diagnostic tests annually. Their commitment to swift and accurate testing supports a wide array of clients, from healthcare providers to pharmaceutical companies.
Building a Healthier Future Together
With this alliance, both Pangea Laboratory and Unilabs are not just enhancing patient care through advanced diagnostics but are also driving a significant shift in how cancer detection is approached across Europe. The Bladder CARE™ Assay constitutes an essential tool that adds to the arsenal against cancer, reflecting a promising future for non-invasive diagnostic methods in healthcare.
Frequently Asked Questions
What is the Bladder CARE™ Assay?
The Bladder CARE™ Assay is a non-invasive diagnostic test that detects bladder cancer and UTUC using DNA methylation biomarkers from urine samples.
Who are the partners in this collaboration?
Pangea Laboratory and Unilabs have partnered to provide the Bladder CARE™ Assay in Switzerland and beyond.
How does the assay benefit patients?
The assay is covered by insurance, increasing accessibility for patients and allowing for easy sample collection from home.
What are the accuracy metrics for the Bladder CARE™ Assay?
The assay boasts a sensitivity, specificity, and negative predictive value exceeding 93% for detecting bladder cancer and UTUC.
When will the Bladder CARE™ Assay be available?
The assay is set to be introduced in Switzerland, with plans for a broader rollout throughout Europe.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Recent Articles
- Australian Central Bank's Interest Rate Strategy Insights
- Eloro Resources Secures $3.78 Million in Latest Placement
- CCR Reports Impressive Growth and Operational Highlights
- Levine Leichtman Capital Partners Celebrated as Top Investor
- Ignacio del Pino Takes Charge as New Chief Investment Officer
- CCR Reports 3rd Quarter Growth and Future Plans
- Cathie Wood's ARK ETFs Make Strategic Moves with Stocks
- U.S. Dollar's Continued Strength Amid Economic Performance Insights
- Hemlo Explorers Secures Funding for Major Exploration Projects
- Tiffany Haddish Set to Emcee Stand Together Event in November
- Eisai Moves Forward with LEQEMBI for Alzheimer’s Care
- Daiso Celebrates New Store Opening with Exciting Promotions
- Mynaric AG Faces Investigation Amid Securities Fraud Claims
- Exploring Sustainable Urban Futures: World Cities Day 2024
- Portnoy Law Firm Investigates Customers Bancorp for Fraud
- Eisai Advances Leqembi BLA Submission for Home Administration
- Eisai Advances Alzheimer's Treatment with Leqembi Dosing Submission
- New Trade Opportunities for New Zealand with Gulf Cooperation Council
- Exploring Healing Through Movement: Human Garage & W.O.W.
- Newbury Street II Acquisition Corp. Prices $150M IPO with Nasdaq Listing
